Dr. Reddy's Announces the Launch of Gemcitabine for Injection

Dr. Reddy's Laboratories RDY announced today that it has launched Gemcitabine for Injection (200 mg/vial and 1 g/vial), a bioequivalent generic version of Gemzar®* in the US market on July 25, 2011, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Gemcitabine for injection. The Gemzar® brand had U.S. sales of approximately $634 million for the most recent twelve months ending May 31, 2011 according to IMS Health.